Vital Images, Mirada Solutions to integrate imaging technologies

TriMed Staff | | Health Imaging | Molecular Imaging
Medical imaging software company Vital Images Inc. has signed an agreement with Mirada Solutions Ltd. to integrate Mirada's positron emission technology (PET) and image fusion software into Vital Images' Vitrea software.

Vital Images, based in Minneapolis, plans a commercial launch of the new product in 2004.

 Mirada's technology is designed to fuse images from the same or different imaging modalities, such as MRI, PET or CT, from datasets acquired at different times or from datasets generated on equipment from different manufacturers.

 Mirada's recent acquisition by CTI Molecular Imaging Inc. "means that the Vital Images relationship represents an even greater distribution opportunity for PET and molecular imaging technology," said Mirada Solutions CEO Chris Behrenbruch. Mirada Solutions is based in Oxford, England.

TriMed Staff

Related Content

New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
ALS drug repurposed for PET imaging
New radiotracer has 'incredible potential' to improve management of spinal cord injuries
Frontotemporal dementia often misdiagnosed due to misinterpretations of imaging
Endometriosis imaging agent impresses at clinical trials

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.